LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

Li Fraumeni Syndrome Clinical Trial

— LIFSCREEN  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01464086
• Other study ID #: CSET2011/1748
• Status: Completed
• Phase: Phase 3
• Start date: October 27, 2011
• Est. completion date: October 9, 2017

Study information

• Verified date: February 2021
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 107
• Est. completion date: October 9, 2017
• Est. primary completion date: March 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 71 Years

Eligibility

Inclusion Criteria:

• P53 mutation

Related Conditions & MeSH terms

• Li Fraumeni Syndrome
• Li-Fraumeni Syndrome
• Syndrome

Intervention

Other:
• whole body MRI
whole body MRI at inclusion, one and two years

Locations

Country	Name	City	State
France	Institut Gustave Roussy	Villejuif

Sponsors (1)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cancer incidence	cancer incidence during the first 3 years	3 years